The Effect-Site Concentration of Remifentanil Blunting Cardiovascular Responses to Tracheal Intubation During Etomidate Anesthesia: A Dose-Finding Study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054565

Enrollment

Unknown

Registered

2021-12-20

Start date

2021-12-16

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular responses to tracheal intubation

Interventions

Experimental group:remifentanil

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Patients with ASA I-II who need general anesthesia and tracheal intubation can be enrolled in this study; 2. Aged 18 to 64 years.

Exclusion criteria

Exclusion criteria: 1. Intraventricular bradycardia (HR30kg/m2 or = 140mmHg and/or DBP >= 90mmHg); 11. Entrance hypotension (MAP = 100bpm).

Design outcomes

Primary

Measure	Time frame
Blood pressure;Heart rate;	—

Secondary

Measure	Time frame
Bispectral index;damage index;Dosage of remifentanil;Adverse reaction;	—

Countries

China

Contacts

Public ContactLuo Tao

Peking University Shenzhen Hospital

luotao_wh@yahoo.com+86 13510820779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026